Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | MicrobiomeTrials← Back to trialsNCT03284385
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2019-01-29Est. Completion: 2026-03-01
Enrollment target: 18 participants Locations- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Northwestern University, Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
- University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
- University of Kansas Clinical Research Center, Fairway, Kansas, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is gi…
Gilbert, United StatesEst. completion Apr 2028
Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v7
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients …
Fairbanks, United StatesEst. completion Jul 17, 2018
Brigham and Women's Hospital, Boston, Massachusetts, United StatesBeth Israel Deaconess Medical Center, Boston, Massachusetts, United StatesDana-Farber Cancer Institute, Boston, Massachusetts, United StatesWayne State University/Karmanos Cancer Institute, Detroit, Michigan, United StatesWeisberg Cancer Treatment Center, Farmington Hills, Michigan, United StatesSiteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United StatesSiteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United StatesWashington University School of Medicine, St Louis, Missouri, United StatesSiteman Cancer Center-South County, St Louis, Missouri, United StatesSiteman Cancer Center at Christian Hospital, St Louis, Missouri, United StatesLaura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United StatesUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United StatesVanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United StatesVanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United StatesUT MD Anderson Cancer Center, Houston, Texas, United StatesAdenocarcinomaProstate NeoplasmsProstate CancerRenal Cell CarcinomaVon Hippel Lindau Disease
This study will evaluate the accuracy and effectiveness of an experimental tracking device for locating abnormalities du…
Bethesda, United StatesCompleted Aug 2, 2028